SSTR

In this video, Dr. Bardiès demonstrates the clinical application of nuclear medicine dosimetry using an anonymized patient dataset.

In this video, Dr. Bardiès explains the steps of a clinical dosimetry workflow in nuclear medicine.

In this video, Dr. Bardiès gives a short introduction about the concept of dosimetry for radiopharmaceuticals and explains the terminology routinely used for the procedure.

Advancements in gallium-based radiopharmaceuticals are transforming the landscape of oncologic diagnostics, with several agents already in routine clinical practice and more in development. Explore the techniques employed to produce the gallium-68 on both small and large scales to satisfy clinical and research needs.

In this infographic, the focus is on circulating biomarkers for neuroendocrine neoplasms, which are highly clinically relevant. Learn all about them.

The following slide kit outlines the principles and steps for somatostatin receptor-based imaging, specifically in managing neuroendocrine tumors.

Learn more about targeted radiopharmaceutical therapy and the mechanism of action of radiotherapeutic agents used for the treatment of tumors expressing specific receptors on their surface.

Somatostatin signaling is an important pathway involved in the pathophysiology of neuroendocrine tumors (NETs) that allows a personalized theranostic approach to their management.

Explore this interactive patient case to learn more about the diagnosis and management of pancreatic neuroendocrine tumors. This case study, which covers several lines of treatment, was kindly provided by Dr. Jaume Capdevila.

This e-book chapter provides an overview of the current knowledge on diagnosing and treating gastroenteropancreatic and pulmonary neuroendocrine tumors, focusing on the indications of radiopharmaceutical therapy. Two clinical cases are also included.

Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Highly precise radiopharmaceuticals can be used to effectively diagnose or treat tumors expressing specific receptors on their surface. Watch the video to learn more about their mode of action (MoA).